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Abstract: Many pathogens (virus, bacteria, fungi, or parasites) have developed a wide variety of
mechanisms to evade their host immune system. The budding yeast Saccharomyces cerevisiae has
successfully been used to decipher some of these immune evasion strategies. This includes the
cis-acting mechanism that limits the expression of the oncogenic Epstein–Barr virus (EBV)-encoded
EBNA1 and thus of antigenic peptides derived from this essential but highly antigenic viral protein.
Studies based on budding yeast have also revealed the molecular bases of epigenetic switching or
recombination underlying the silencing of all except one members of extended families of genes
that encode closely related and highly antigenic surface proteins. This mechanism is exploited by
several parasites (that include pathogens such as Plasmodium, Trypanosoma, Candida, or Pneumocystis)
to alternate their surface antigens, thereby evading the immune system. Yeast can itself be a
pathogen, and pathogenic fungi such as Candida albicans, which is phylogenetically very close to
S. cerevisiae, have developed stealthiness strategies that include changes in their cell wall composition,
or epitope-masking, to control production or exposure of highly antigenic but essential polysaccharides
in their cell wall. Finally, due to the high antigenicity of its cell wall, yeast has been opportunistically
exploited to create adjuvants and vectors for vaccination.
Keywords: yeast; Saccharomyces cerevisiae; immune system; immune evasion; adjuvant for vaccines;
yeast cell wall; G-quadruplexes (G4); G4 ligands; nucleolin (NCL); Epstein–Barr virus (EBV);
oncogenic viruses
1. Yeast as a Popular Model for Basic Research and Chemical Genetics Approaches
For many decades, yeast has been a popular and powerful model to study basic cell biology
mechanisms that include DNA replication [1] and transcription [2], cell cycle regulation [3], vesicular
transport [4], autophagy [5], and cell death [6]. This is nicely illustrated by the numerous yeast scientists
in the list of Nobel Prize laureates, in particular in Medicine and Physiology [7]. For about 20 years,
yeast has also been exploited as a tool for chemical genetics approaches, in particular in the field of
humans and animal disorders. Hence, yeast-based approaches to model and exploit physiopathological
mechanisms responsible for several human diseases have been successfully developed. The most
evident situations are when the key physiopathological factors are functionally conserved from yeast
to humans, for example in the field of inherited mitochondrial disorders [8,9]. However, yeast models
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based on the expression of key players that do not exist in yeast are also possible, as for example
yeast models for Huntington or Parkinson diseases ([10–12]; for review: [13]). Altogether, numerous
yeast-based models for human disorders have been developed and successfully used for both the
identification of candidate drugs and chemical probes (e.g., yeast model for prion-based diseases [14,15]),
or of new physiopathological actors and thus of new intervention points and therapeutic targets (e.g.,
yeast model for Huntington disease [10]). As for viruses and parasites, in particular those affecting
humans, some yeast-based models were also instrumental for deciphering various aspects of their
biology [16], including, rather unexpectedly, their ability to evade the immune system [17]. In addition,
yeast can also be a pathogen, and pathogenic fungi such as Candida represent a serious threat to
human health. One of the Achilles heel of these pathogenic yeasts is their cell wall, which is at the
same time essential for yeast growth and highly antigenic. Hence, as most if not all the pathogens,
pathogenic yeasts have developed various strategies to evade the host immune system. Finally, the
high antigenicity of yeast cells, due to their cell wall, has been exploited as novel alternatives for the
development of vaccines. All these aspects of the link between yeast and immune system modulation
are the topic of this review article and are summarized in Figure 1: let us sneak out for happy hour.
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humans and animals. Its cell wall is highly antigenic, and yeast has developed various mechanisms 
of epitope-masking to evade the host immune system. 3. Yeast is a tool for modelling the mechanism 
that allows immune evasion of the Epstein–Barr virus (EBV). This system has been successfully used 
to isolate drugs interfering with EBV stealthiness and to identify host cell factors involved in immune 
evasion of this oncovirus. 4. The antigenicity of the yeast cell wall has been biotechnologically 
exploited as an adjuvant for vaccination. In addition, yeast cells, heat-killed or alive, have been 
directly used as vectors for various antigens, hence combining the vaccine and the adjuvant in the 
same particle (VLP, virus-like particle; WRY, whole recombinant yeast; YSD, yeast surface display). 
2. The Long-Lasting Love Affair between EBV and the Budding Yeast Saccharomyces Cerevisiae 
The Epstein–Barr gammaherpesvirus (EBV) is the first oncogenic virus discovered in humans 
[18–20]. Indeed, EBV has been known for more than 50 years to be tightly associated with certain 
human malignancies and, as of today, EBV is still one of the most effective means for transforming 
and immortalizing human B-cells. More than 90% of the human population worldwide is infected by 
EBV whose primary infection remains asymptomatic most of the time but, when it occurs in teenagers 
and adults, it can be responsible for the infectious mononucleosis, also known as “kissing disease” as 
Figure 1. Scheme sum arizing the vari lore and modulate i mune response
and im une vasion. Yeasts are fungi an , ss a ce l a l that surrounds their plasma
me brane, in ad ition to the typical feat r f tic cells (that includ existence of a nucleus,
mitochondria, vacuoles which are hydrolytic r a elles si ilar to the lysosomes in higher eukaryotes,
endoplasmic reticulum etc.). 1. Yeast is a odel syste for echanisms based on gene repression and
switching that allow im une evasion of any parasites. 2. Yeast can also be a pathogen, notably for
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epitope-masking to evade the host immune system. 3. Yeast is a tool for modelling the mechanism that
allows immune evasion of the Epstein–Barr virus (EBV). This system has been successfully used to
isolate drugs interfering with EBV stealthiness and to identify host cell factors involved in immune
evasion of this oncovirus. 4. The antigenicity of the yeast cell wall has been biotechnologically exploited
as an adjuvant for vaccination. In addition, yeast cells, heat-killed or alive, have been directly used as
vectors for various antigens, hence combining the vaccine and the adjuvant in the same particle (VLP,
virus-like particle; WRY, whole recombinant yeast; YSD, yeast surface display).
2. The Long-Lasting Love Affair between EBV and the Budding Yeast Saccharomyces cerevisiae
The Epstein–Barr gammaherpesvirus (EBV) is the first oncogenic virus discovered in
humans [18–20]. Indeed, EBV has been known for more than 50 years to be tightly associated
with certain human malignancies and, as of today, EBV is still one of the most effective means for
transforming and immortalizing human B-cells. More than 90% of the human population worldwide
is infected by EBV whose primary infection remains asymptomatic most of the time but, when it occurs
in teenagers and adults, it can be responsible for the infectious mononucleosis, also known as “kissing
disease” as the virus is spread through saliva. Mononucleosis is a self-limiting lymphoproliferative
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disorder that in some cases can be quite harmful. Like all gammaherpesviruses, EBV is latent
thanks to its ability to evade the host immune system, thus persisting in most infected people as a
lifelong asymptomatic infection [21]. However, it can be responsible for severe lymphoproliferative
disorders, notably in patients suffering some forms of immune suppression such as grafted patients
receiving immunosuppressive treatments, or human immunodeficiency virus (HIV)-infected people.
EBV has also been associated, most of the type in combination with a co-factor, to various cancers
that include the Burkitt and Hodgkin lymphomas, nasopharyngeal carcinoma and 10% of gastric
cancers [22]. Altogether, more than 1% of cancers are associated with EBV, as at least 200,000 new cases
of EBV-associated cancers are estimated per year worldwide [23], as compared to an estimated total of
18 million cancers. For all these reasons, various aspects of EBV biological cycle, including the regulation
of its genome replication and maintenance, induction of its lytic cycle, or mechanisms at the basis of its
ability to evade the immune system, that are related to its tumorogenicity have been the subject of
extensive studies. For all these aspects of EBV biology, the use of the budding yeast S. cerevisiae model
has been instrumental for more than 30 years and fruitfully contributed to decipher some key aspects of
EBV life cycle. This has been recently presented in a review article [24] and includes the identification
of (i) autonomous replication sequences (ARS) in the circular double strand DNA episome of EBV [25],
(ii) genes encoding human proteins required for EBV genome maintenance [26] and, (iii) the interplay
of these host factors with the virally encoded Epstein-Barr nuclear antigen 1 (EBNA1) protein which
is the genome maintenance protein of EBV [27,28]. In addition, the transcriptional activity of the
BamHI Z Epstein-Barr virus replication activator (ZEBRA), an EBV-encoded transcription factor at
the top of a cascade event leading to expression of EBV lytic cycle genes [22], has been recapitulated
in budding yeast, allowing the identification of the regions of ZEBRA crucial for its transcription
factor activity as well as two natural EBV promoters that are activated by ZEBRA, which include the
promoter of ZEBRA itself [29,30]. Budding yeast has also been instrumental to study the oncogenic
activity of EBV, in particular to show that BGLF4, the EBV representative of the CHPK (conserved
herpesvirus-encoded protein kinase), displays a CDK (cyclin-dependent kinase)-like activity. This has
been shown by showing that BGLF4 is able to complement, in yeast, the cell cycle arrest induced by
defects in Cdk1/Cdc28, the main yeast CDK that controls the progression through all the phases of the
budding yeast cell cycle and which is the homolog of CDK1/CDC2 in humans [31]. This CDK-like
activity of BGLF4 most probably contributes to the ability of EBV to promote tumor formation by
inducing the phosphorylation of the retinoblastoma (Rb) tumor suppressor gene and of the lamin
A/C, two events normally catalyzed by human CDKs and that are necessary for progression into the
cell cycle. In support of this model is the observation that Rb is properly phosphorylated in cells
infected by EBV [32]. Finally, more recently, budding yeast has been successfully used to investigate the
mechanisms at the basis of the immune evasion of EBV. This will be the subject of the following section.
3. Use of Budding Yeast to Model and Decipher the Mechanisms at the Basis of EBV Stealthiness
As stated above, EBV is a latent virus that evades the host immune system but, fortunately, it has
an Achilles heel: its aforementioned genome maintenance protein EBNA1. Indeed, due to its crucial
role in both EBV genome replication and maintenance, EBNA1 must be expressed in all EBV-infected
cells or the virus would be lost upon host cell division [27,28,33]. On the other hand, EBNA1 is highly
antigenic and cytotoxic CD8+ T cells directed towards EBNA1 epitope are present in every EBV-infected
individuals. Hence, EBV evolved a strategy to limit the expression of EBNA1 to the minimal level to
fulfil its essential function in replication and maintenance of the viral genome and, at the same time,
to minimize its detection by the immune system. This stealthiness strategy is based on the ability
of EBNA1 to limit in cis the translation of its own mRNA and involves the central glycine-alanine
repeat (GAr) of EBNA1 [34,35]. The GAr is dispensable for the essential functions of EBNA1 in EBV
genome replication and maintenance, but is critical for EBNA1 stealthiness as an EBNA1 that lacks
the GAr (EBNA1∆GAr) is unable to evade the immune system (Figure 2A) [34–37]. Deciphering this
mechanism is the goal of several teams as it is commonly considered to be a therapeutic target to unveil
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EBV-infected cells, including tumor cells from EBV-related cancers, to the immune system. Hence
there was a clear need for a convenient eukaryotic cell-based assay that would allow performance of
high-throughput screenings that include both drug screening (to isolate chemical probes that would
serve as tool to study this mechanism of stealthiness and also candidate drugs to unveil EBV-related
cancers to the immune system) and genetic screening (to isolate host cell factors involved in this process
and that may therefore serve as original therapeutic targets). Indirect evidence from the literature ([38]
reviewed in [24]) suggested that budding yeast might be a good option as GAr-based inhibition of
translation in cis appears to be operant in this model organism. These preliminary observations also
suggested that the mechanism of GAr-based inhibition of translation, which is at the basis of immune
evasion of EBNA1, and thus of EBV, is conserved from yeast to humans. For all these reasons, a yeast
model that recapitulates all the aspects of GAr-based inhibition of translation, including GAr length
dependency, has been developed [17,39]. This model is based on the use of the ADE2 reporter gene [40].
Indeed, this yeast gene encodes Ade2p, one of the enzymes of the adenine biosynthesis pathway
which, when absent, leads to red color of yeast cells grown on rich medium (hence supplemented in
adenine) due to accumulation of the otherwise cell-limited phosphoribosylaminoimidazole, a metabolic
by-product of the adenine biosynthesis pathway, which appears red upon oxidation. In contrast, when
expressed at a sufficient level, the ADE2 gene leads to white yeast cells whereas any intermediate level
of expression leads to a pink color whose intensity is inversely proportional to the expression of Ade2p
(Figure 2B). This reporter gene has also been chosen because it encodes a protein that is very stable, as
EBNA1. Then, sequences encoding GAr domains of different lengths have been fused to the ADE2
reporter gene. As in human cells, this led to a GAr length-dependent cis inhibition of the translation of
GAr-ADE2 mRNA which is shown by a gradient of pink color of yeast colonies: a short GAr (21GAr;
21 residues) only slightly affects the expression of Ade2p, thereby leading to light pink colonies, a
43GAr leads to medium pink colonies whereas yeast cells expressing a full-length GAr-ADE2 fusion
(235GAr; 235 residues) as a sole source of Ade2p form dark pink colonies (Figure 2B). Of note, similarly
to situation in human cells, GAr does not affect transcription nor mRNA or protein stability. Hence,
it specifically affects translation, in cis and in a length-dependent manner. This represented a first
validation of the yeast model and further suggested that, should host cell factors involved in GAr-based
inhibition of translation exist, then they are conserved from yeast to humans.
The yeast model was further validated since it allowed the identification drugs that specifically
interfere with the GAr-based limitation of translation both in yeast and human cells, and that later on
turned to be also able to interfere specifically with the GAr-based limitation of antigen presentation by
the major histocompatibility complex (MHC) class I (Figure 2C, top) [39].
On the ground of these validations, a genetic screening was performed based on this yeast model
for the mechanism at the basis of EBV immune evasion in latency. The rationale was to isolate host
cell factors potentially involved in this mechanism and that could thus represent therapeutic targets
to unveil EBV-related cancers, and more generally EBV-infected cells, to the immune system [17,41].
This way, nucleolin (Nsr1p in yeast, NCL in humans) was identified (Figure 2C, bottom) as the first
host cell factor critically involved in EBNA1/EBV immune evasion. Indeed, in both the yeast model
and human cells, overexpression of nucleolin exacerbated the inhibitory effect of GAr on translation
whereas its down-regulation led to alleviation of this effect and of GAr-based limitation of antigen
presentation by the MHC class I. Interestingly, at the time of this discovery, nucleolin was already
known as the first G-quadruplex (G4)-binding protein identified [42,43] and G4 had been recently
characterized in the GAr-encoding sequence of EBNA1 mRNA [44]. G4 are non-canonical secondary
structures that may form in guanine-rich nucleic acids, both in DNA and RNA. G4 are formed by the
stacking of G-quartets which consists of a planar arrangement of four guanines connected by Hoogsteen
hydrogen bonds and stabilized by a central cation, most often a K+ (Figure 3A). G4 structures within
G-rich DNA or RNA have been implicated in gene regulation where they can affect transcription,
splicing or translation [45–50]. Hence, was tested the possibility that NCL binds to G4 that form in
the GAr-encoding sequence of EBNA1 mRNA, thus leading to inhibition of its translation. Based on
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RNA pulldown [51] and proximity ligation assay (PLA) adapted to protein/RNA interaction [52], this
model was validated (Figure 3B). Of note, this model fully explains the GAr length dependency of
the cis inhibition of translation as the longer GAr is, the more it forms G4 (the full-length 235GAr
being reported to form up to 13 G4 in vitro [44]), hence the more NCL proteins it could bind. In any
event, this model also suggested that the NCL/G4 of EBNA1 mRNA interaction represents a bona fide
intervention point to unveil EBV-related cancers to the immune system. This putative therapeutic
target was validated since some G4 ligands, which include PhenDC3, by preventing binding of NCL to
G4 of EBNA1 mRNA, interfere with the GAr-based inhibition of translation and limitation of antigen
presentation by MHC class I (Figure 3B) [41]. Since PhenDC3 is a benchmark G4 ligand [53], new
G4 ligands active in this system and with patentable structures have been investigated. This way,
bis(acylhydrazones) PhenDH2 and PyDH2 (Figure 3C) have been developed and shown to interfere
even more efficiently than PhenDC3 with the NCL/G4 of EBNA1 mRNA interaction and thereby with
GAr-based limitation of protein expression and antigen presentation [54]. In addition, these two
compounds present a lower toxicity than PhenDC3. Of note, the ability of G4 ligands to interfere with
the NCL/G4 of EBNA1 mRNA interaction is not a general property of all G4 ligands as most novel
PhenDC3 derivatives, despite strong binding and stabilization of G4-RNA in vitro, did not present
this ability and thus were not able to interfere with EBNA1 stealthiness [54]. This is also true for
pyridostatin (PDS), another benchmark G4 ligand, and probably due to a different mode of binding
of all these compounds on G4 [41]. Förster resonance energy transfer (FRET)-based experiments on
single RNA molecules may help to clarify and provide molecular bases to explain such a difference
between various G4 ligands [55,56].
Hence, starting from a naive model based on budding yeast, which obviously has no common
evolutionary history with EBV, a human virus, the first host cell factor involved in EBV immune
evasion, NCL, has been identified and its mechanism of action deciphered [17,41]. Based on these
findings, candidate drugs able to interfere with EBV immune evasion have been isolated [41,54].
Finally, the results obtained in yeast about the role of NCL binding on G4 of EBNA1 mRNA were
at the basis of a study based on human cells and dedicated to the relationship between cellular
compartmentalization and production of antigenic peptides that has suggested that nuclear processing
of nascent transcripts determines synthesis of full-length proteins and antigenic peptides [57]. Indeed,
this work indicates that antigenic peptides may derive from a nuclear non-canonical translation event
that is independently regulated from the synthesis of full-length proteins and further show that G4
are exploited to control mRNA localization and translation by distinguishable mechanisms that are
targets for viral immune evasion. This way, once again, budding yeast has been instrumental to model
pathophysiological mechanisms and identify new therapeutic targets and candidate drugs. In line, G4
have been discovered and described in vitro for a long time by biophysicists but their functional role
in various biological processes has emerged only relatively recently and, again, budding yeast played
an important role in this expanding scientific field [58]. Notably, the role of G4 in genome stability
and of the ability of some helicases to bind and unwind these particular secondary structures of DNA
have been studied in detail in budding yeast. Indeed, repetitive DNA sequences, the most prominent
and thus the most vulnerable ones being the rDNA repeats, telomeres, minisatellites and transposable
elements, are a major threat to genome stability as they often drive chromosomes rearrangements
therefore leading to various disorders. G4 can modulate the function of these repetitive DNA loci
by affecting their transcription, replication and stability (for reviews, [58,59]). In particular, the Pif
helicase family which play multiple roles in the maintenance of nuclear and mitochondrial DNA in
eukaryotes has been extensively studied in budding yeast S. cerevisiae [60]. Hence, ScPif1 (S. cerevisiae
Pif1) has been involved in replication through its ability to resolve barriers to replication such as G4,
and thus reduces genetic instability at these sites [61–65].
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Figure 2. Rationale of the yeast-based assay for immune evasion of EBNA1/EBV. (A) Schematic
representation of EBNA1 and EBNA1∆GAr proteins that highlights the crucial role of the central
GAr (glycine-alanine repeats) domain for immune evasion: EBNA1∆GAr is still able to fulfil its
essential functions in viral genome maintenance and replication but does not evade the immune system.
(B) Principle of the ADE2 reporter gene-based assay. Yeast cells that express a normal level of Ade2p
(the product of the ADE2 gene) form white colonies whereas cells that do not express Ade2p (ade2∆ cells)
form red colonies due to the accumulation and consecutive oxidation of a by-product of the adenine
biosynthesis pathway. Any intermediate level of Ade2 leads to pink colonies whose color intensity is
inversely proportional to the Ade2p level. GAr domains of various lengths were fused to the ADE2
gene. As for EBNA1 in human cells, GAr inhibits the translation of its own mRNA in yeast. Please note
that this effect is length-dependent as in human cells, as the longest GAr tested (235GAr) leads to a
strong inhibition of translation, giving rise to dark pink colonies, whereas the shortest GAr (21GAr)
gives light pink colonies. For screening purpose, the 43GAr, which gives pink colonies, has been used.
(C) Principle of the pharmacological and drug screenings based on the 43GAr-ADE2 yeast strain. Drugs
able to interfere with GAr ability to inhibit translation, such as doxorubicin (DXR) [39] or various
G-quadruplex ligands [41,54] lead to whiter colonies that express more 43GAr-Ade2p. In contrast, the
overexpression (OE) of host cell genes involved in the GAr inhibitory effect on translation, such as
NSR1 that encodes the yeast nucleolin (NCL in humans), leads to redder colonies as the inhibition
of 43GAr-ADE2 expression is exacerbated. Finally, the knockout (KO) of the NSR1 gene relieves the
inhibitory effect of GAr, leading to white colonies.
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Figure 3. Model of nucleolin (NCL) role in EBNA1 immune evasion and of the mode of action of G4
ligands. (A) Structure of a G-quadruplex (G4). G4 are formed by the stacking of G-quartets that consists
of a planar arrangement of four guanines connected by Hoogsteen hydrogen bonds and stabilized
by a central cation, most often a K+. (a) Sequence of the repeated G4-forming motif within the GAr
domain-encoding sequence of EBNA1 mRNA. (b) Structure of a G-quartet, formed by self-association
of four guanine residues (blue) with metal cation (K+); R = ribose residue. (c) Schematic depiction of a
putative two-quartet G4 structure formed in the GAr domain-encoding sequence of EBNA1 mRNA;
nucleobase colors: G, blue; A, red; C, green. (B) Model of the role of NCL in EBNA1/EBV immune
evasion and of the ability of some G4 ligands to interfere with this mechanism. The cellular NCL
protein binds to G-quadruplex (G4) that form in the GAr-encoding sequence of the viral EBNA1 mRNA,
thereby leading to inhibition of the translation of the latter, thus leading to a limited production of
EBNA1-derived antigenic peptides and this way to immune evasion of EBV-infected cells. Some
G4 ligands, such as PhenDC3, PhenDH2 or PyDH2, prevent the binding of NCL on G4 of EBNA1
mRNA, thereby interfering with the GAr ability to inhibit translation of its own mRNA, which results
in an increase in the production of EBNA1 protein and of EBNA1-derived antigenic peptides. This
may unveil EBV-infected cells to the immune system. (C) PhenDC3, which is active against GAr [41],
does not display an original chemical structure as it is a benchmark G4 ligand. In contrast, PhenDH2
and PyDH2, which are less toxic and more active against GAr than PhenDC3, represent patentable
compounds [54].
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4. Yeast Provided Key Insights into the Molecular Mechanisms of Gene Repression and
Switching at the Basis of Immune Evasion of Some Parasites
The ability of many parasites, which includes many pathogenic protozoan and fungi such as
Plasmodium, Trypanosoma, Candida, or Pneumocystis, to evade the host immune system is key to their
success and pervasiveness. Their genomes contain large family of genes encoding closely related
surface proteins (e.g., VAR genes in Plasmodium [66–69], variant surface glycoprotein (VSG) genes
in Trypanosoma [70], major surface glycoprotein (MSG) genes in Pneumocystis [71,72]) and exquisite
regulatory mechanisms have been developed so that, at any time, only one of these genes is expressed
due to efficient mechanisms that silence all the other genes of the family. As these surface proteins are
immunogenic, rare switching to other members of the gene family favor the immune evasion of the
pathogen but, for most of them, both the mechanisms allowing gene silencing and switching are poorly
understood. However, studies in the budding yeast S. cerevisiae have revealed similar mechanisms of
gene repression and switching, which involve either epigenetic switching or recombination, and have
therefore provided significant insights into the molecular bases of these phenomena [73]. Briefly, gene
silencing is mediated by compact heterochromatin formation that is re-established after cell division. Of
note, the aforementioned families of genes are located mostly or exclusively in the subtelomeric regions
of the chromosomes [73], whereas some of the very few located elsewhere are surrounded by telomeric
repeats [74]. Telomeres are long-known sites of gene silencing and this telomere position effect (TPE)
has been extensively studied in S. cerevisiae [75]. Importantly, unlike many higher eukaryotes, DNA
methylation and RNAi-based mechanisms do not play a role in the repression of subtelomeric genes
in budding yeast. Hence, due to these particularities, one may consider S. cerevisiae an irrelevant
model organism for epigenetics in higher eukaryote. However, these differences make budding yeast
quite relevant for modelling the antigenic variation of parasites discussed here, as DNA methylation
and RNAi do not seem to contribute to the silencing of the variance genes [68,75]. Also, one of the
key questions when it comes to selectively express only one gene of an extended gene family is the
mechanism that allows such a selectivity and clues again came from budding yeast S. cerevisiae where
clear relationship exists between gene expression and gene position in the nucleus, in particular for
telomeric and subtelomeric sequences [76]. Indeed, in budding yeast, due to a handful of proteins,
which include Ku and some nuclear pore components, the telomeres cluster in several compartments at
the nuclear periphery where genes are silenced and translocation of telomeres inside the nucleoplasm
is associated with loss of repression of the telomeric genes [76,77]. Interestingly, a similar clustering of
the inactive VSG genes in Trypanosoma or of the inactive VAR genes in Plasmodium has been observed,
and the active VAR genes leave these clusters. However, they remain quite close to the repressed
cluster, and still at the nuclear periphery, suggesting a slightly different regulatory mechanism [68,69].
Hence, the study of telomeric gene silencing have provided a basic framework for the understanding of
the silencing of and epigenetic switches within extended families of genes that encode major parasite
antigens. Another important mechanism to switch from one member of the family to another is DNA
recombination. This particular mechanism has been extensively studied in budding yeast as it is
involved in the mating-type switching [78], a process that ensures that both haploid types (Mata and
Matα) persist in order to allow mating, as, in the wild, S. cerevisiae preferentially grows as a diploid.
In this case, a similar constitutive repression of donor genes exists that, to be expressed, need to
be translocated to an active site by a DNA recombination event that is favored by the homothallic
switching endonuclease (HO), thereby leading to mating-type switching. Here again, budding yeast
S. cerevisiae provided a model mechanism for the role of DNA recombination which seems especially
important for the epigenetic switching within MSG genes in Pneumocystis in which the expression site
also determines the expressed variant [71,72].
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5. Yeast as a Pathogen: Its Own Strategy to Evade the Immune System
Yeast can also be a pathogen for humans or other animals and fungi such as Candida albicans
(which is genetically and morphologically very close to S. cerevisiae) or from the Aspergillus genus
represent a major threat for public health, especially in immune-compromised individuals. The fungal
cell wall, which plays an essential role in fungal morphogenesis and resistance to osmotic shock,
represents around 30% of the yeast cell dry weight, up to 50% of the cell volume and polysaccharides
represent over 90% of its components. These polysaccharides are the molecular scaffold that supports
cell wall proteins, lipids and superficial components [79,80]. The cell wall crucial and active role
during fungal infection, in humans and other animals, has been recognized for a long time (Figure 4).
Indeed, the first step in the development of an immunological response against pathogenic fungi
involves recognition of some component of their cell wall by phagocytic cells from the innate immune
system. Innate immune cells exploit a range of Toll-like receptors (TLRs, which include TLR-4 and
TLR-2) as well as C-type lectin receptors (CLRs) such as Dectin-1, DC-sign, and mannose receptors,
to detect the so-called pathogen-associated molecular patterns (PAMPs), many of which in fungi are
components of the cell wall that include β-glucans, mannans, mannoproteins and chitin [81,82]. In
this respect, some cell wall components, in particular β-1,3-glucan, can be considered to be bona fide
Achilles heels of pathogenic fungi as they are essential, or at least of extreme importance, for fungi
survival and, at the same time, highly immunogenic. Consequently, changes in PAMP exposure at the
fungal cell surface affect immune recognition, thereby influencing yeast ability to colonize its host.
Hence, among various strategies to evade the immune system, changing cell wall composition or
masking some highly antigenic cell wall components have been developed by various pathogenic fungi.
For example, some fungi have developed a strategy based on covering β-1,3-glucan and chitin by
various molecules that include mannans [83–90] or α-1,3-glucan [91], thereby affecting its recognition
by the Dectin-1 receptor. Another strategy developed by the yeast Histoplasma capsulatum is to secrete
Eng1, an endo- β-1,3-glucanase which, by trimming β-1,3-glucan fragments exposed at the fungal cell
surface, minimize their recognition by Dectin-1 [92].
Interestingly, this cell-surface epitope-masking can be induced by alterations in the environment.
Hence C. albicans reacts to the change in carbon source from glucose, which is mostly absent in vivo, to
lactate, which is the major carbon source in the blood or in vaginal environment, by masking β-glucan
thereby protecting itself from the host immune response [93,94]. This last case is a nice illustration
of the so-called adaptive prediction or anticipatory response in which certain pathogens, including
pathogenic yeasts from the Candida, Aspergillus, or Histoplasma genera, have evolved anticipatory
behaviors that are triggered by specific signals in the host to prepare themselves against imminent host
challenges. This was nicely reviewed recently [95] and has been proposed to represent a primitive form
of microbial memory which would somehow be reminiscent of the anticipatory response of Pavlov’s
dogs. In the case of C. albicans, this pathogenic yeast is prepared to host-specific conditions such as high
lactate and hypoxia and developed an anticipatory response that leads to epitope-masking once inside
its host. Interestingly, this type of anticipatory response seems to have been developed preferentially
in pathogenic fungi such as C. albicans that is likely to have evolved in the mammalian host, whereas
the benign budding yeast S. cerevisiae, which does not have the same evolutionary history, does not
necessarily display the same mechanisms. As an illustration is the fact that glucose represses stress
resistance in S. cerevisiae [96,97], whereas it leads to activation of oxidative stress genes in C. albicans [98].
As a direct consequence, glucose protects C. albicans against killing by circulatory neutrophils in the
bloodstream where the concentration of glucose is relatively high [99].
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Figure 4. Importance of yeast cell wall components in immune detection and vaccine development.
(A) Yeast has evolved a sophisticated cell wall enabling better adaptation to harsh environmental
conditions. Pathogenic fungi can further modify cell wall components to resist host immune response
pressure and cause disease. (B) On the other hand, carbohydrates abundantly found in yeast cell
wall are absent in mammals and poultry birds, enabling efficient recognition of yeast cells by the
host immune surveillance mechanisms, in particular by the innate immune system. This particularity
has been exploited for the development of new adjuvant molecules and yeast-based approaches as
alternatives to alum-adjuvanted subunit vaccines.
6. Biotechnological Exploitation of Yeast to Create Vaccine or Adjuvant for Human and
Animal Vaccination
As stated above, yeast-based approaches have opened unique windows of opportunities to
decipher eukaryotic cell biology and to produce molecules of biotechnological relevance. More recently,
these microorganisms have also found a special place in the vaccinology field. The observation that host
immune response against fungi is robust and evolutionarily conserved in the animal kingdom raised
the question whether yeasts can be employed as platforms for the development of novel prophylactic
and therapeutic strategies against cancer and infectious diseases.
Use of yeast as workhorses for the production of vaccines is an appealing idea for different reasons.
Despite the immune evasion mechanisms aforementioned, innate recognition of fungi leads to strong
adaptive immunity and if host defenses are intact, fungal infections are very rare [100,101]. Moreover,
yeasts have been largely used as probiotics in human and veterinary medicine for preventing infections
by trapping pathogenic bacteria, modifying myeloid cells phenotype, migration and T-cell polarization
capacity [102]. These particularities have been associated with the presence of conserved yeast cell
wall carbohydrates that are absent in hosts including mammals and poultry birds and hence are easily
targeted by immune surveillance mechanisms [103–105]. Due to their immunogenicity and capacity to
modulate immune response, these carbohydrates have great potential as novel adjuvants molecules.
Yeast cell wall comprises an inner layer of β-1,3-glucan chains (80–90%), β-1,6-glucan (8–18%) and
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chitin (1–2%) and an outer layer of mannoproteins (Figure 4) [106]. The inner layer is responsible for
the mechanical strength and elasticity of cell wall whereas the most external layer of the cell wall is
involved in several types of interactions between fungal cells and host immune system [107,108].
β-Glucans enhance resistance to bacterial and parasite infections and play a role in protective
immunity. These molecules are recognized by dectin-1 and complement receptor 3 (CR3) resulting in
fungal opsonization, inflammatory cells influx, Th17, Th1 and cytotoxic T-cell responses [109–111]. For
this reason, β-glucans are promising alternatives to surpass the Th2-type (antibody)-biased responses
elicited by alum-adjuvanted vaccines and have been exploited in clinical conditions requiring the
induction of T cells defenses such as cancer [109–112]. β-Glucans from different sources are easily
obtainable and their derivatives have been extensively developed into vaccine adjuvants or vaccine
delivery systems [113]. However, other yeast polysaccharides, such as mannan and chitin, can also
bind pattern recognition receptors (PRR) and stimulate the immune system [114]. Glucan-mannan
particles (GMP), glucan-chitin particles (GCP) and glucan-chitin-mannan particles (GCMP) have been
generated and showed to be safe in both preclinical and human trials. Pure-glucan particles and
GCP promote comparable levels of Th1 response but GCP have been reported as better inducers
of Th17 immunity. These differences are attributed to the higher levels of chitin found in GCP and
highlight the potential of this polysaccharide as a tool for boosting Th17-type immune response [115].
Yeast mutant strains carrying higher amounts of chitin increase activation of macrophages and show
reduced colonization capacity and virulence [116]. Moreover, chitosan microparticles derived from
chitin increase mucosal and systemic immune responses by improving cell permeability and antigen
stability [117]. Whereas mammalian proteins rarely have exposed mannose residues, fungi use
mannose as their preferred sugar [118]. Interestingly, glycosylated proteins from yeast cell wall
trigger immune mechanisms such as inflammasome activation and pyroptosis [119] and fungi lacking
β-1,3-glucan shed a massive amount of galactomannan [120]. Mannans are highly mannosylated
polysaccharides exposed at the most external layer of yeast cell wall that interact with dendritic cells
(DC) mannose receptor, mannan-binding protein, dectin-2 and DC-specific intercellular adhesion
molecule 3 (DC-SIGN). Mannan polysaccharides induce the release of pro-inflammatory cytokines, DC
maturation [108] and induce better Th1-Th17 signature on inflammatory DC than β-1,3-glucan [120].
Yeast mannan-conjugates give promising results in allergen-specific immunotherapy by enhancing
allergen bioavailability and uptake by DC [121]. In addition, these conjugates are described as efficient
platforms for the development of antifungal vaccines [122].
Development of new vaccine compositions has been generally based on subunit modalities due
to stringent regulatory and safety issues. In these formulations, pathogen antigenic components
are administered with strong adjuvants that have little capacity to induce cellular response and can
provoke aberrant local and systemic reactogenicity in susceptible individuals [123]. Oral vaccines have
attracted a great deal of attention as they enable a higher capacity for mass immunizations during
pandemics at relatively low cost and confer enhanced mucosal and systemic immune responses [124].
Development of new vaccines for farm animals is further driven by cost-effective alternatives that
do not need to be administered individually and can be stored without a cooling chain [125]. In this
context, the inherent immunogenic nature of yeasts combined with their versatility as heterologous
protein expression systems and their probiotic activity might provide innovative strategies to fight
human and animal diseases for which effective vaccines are lacking. Novel ways of employing yeast
against infectious diseases and cancer include the use of virus-like particles (VLP), whole recombinant
yeast (WRY) and yeast surface display (YSD).
Subunit vaccines based on soluble, monomeric proteins often present limitations regarding
immunogenicity that can be overcome by VLP-based approaches [126]. VLP are multimeric complexes
of virus proteins produced by recombinant DNA technology. They have received much attention
as vaccine candidates because they have antigenicity and immunogenicity similar to native virions
but are non-infectious and lack viral genomic material [127,128]. Foreign antigens can be displayed
on VLP surface by genetic engineering or by chemical conjugation. These particles are suitable for
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mucosal immunization due to their resistance to proteolytic degradation and compatibility with
mucosal environment [129]. Yeast VLP scaffolds have been used to display immunogenic antigens
from pathogens such as porcine circovirus [130], rabbit hemorrhagic disease virus [131], coxsackievirus
A6 [132], hepatitis B virus [133], Zika virus [128], chikungunya virus [134], dengue virus [135],
enterovirus [127,136].
Unlike peptide-based vaccines, WRY or YSD-based vaccines do not require special adjuvant [137].
Yeasts are non-toxic and easy-to-grow microorganisms, some species being able to multiply at
physiological temperatures and survive the harsh environmental conditions found in the gastrointestinal
tract. Moreover, yeast cannot acquire or spread genes conferring resistance to antibiotics and are
consequently safer than probiotic bacteria [138]. Recombinant yeasts represent then interesting
tools for developing edible vaccines for human and animals. WRY has attracted high attention for
preventive and therapeutic vaccine formulations against several chronic infections and cancers. In
this approach, yeast cells are used as both production and delivery systems, providing a simple and
affordable vaccine production platform free from complicated and expensive downstream protein
purification steps [112,139]. Kim et al. [129] observed that oral administration of WRY provoked
9–27 times higher antibody titers than purified antigen. Interestingly, both heat-killed and live yeast
generate antigen-specific immune response and elicit equivalent protective immunity, circumventing
the risk of pathogenicity of live vaccines [112]. Tarmogens (targeted molecular immunogen) use
intact heat-inactivated S. cerevisiae cells as vectors to elicit antigen-specific CD4+ and CD8+ T-cell
responses. This approach has been successfully employed to treat patients with chronic hepatitis C
virus infection [140] but did not result in a clinical benefit in patients with chronic hepatitis B [141]. In
preclinical studies, another Tarmogen-based vaccine promoted minimal prophylactic activity against
Mycobacterium tuberculosis but reduced lung pathology and improved survival rates in a therapeutic
model of tuberculosis [142]. Other WRY showed to elicit cell-mediated and/or humoral immune
responses against dengue virus [124], fish nervous necrosis virus [129], porcine epidemic diarrhea
virus [143], infectious bursal disease of poultry [144] and malaria [145].
WRY are also in development for cancers therapies. Yeast expressing human carcinoembryonic
antigen (CEA) has been engineered to circumvent the non-immunogenic nature of cancer-associated
antigens and induced killing of human CEA+ tumor cells in preclinical studies [146–148]. WRY
expressing brachyury, a nuclear transcription factor expressed in a range of human carcinomas and
chordoma, has been tested in a phase I clinical study that demonstrates the safety and efficiency of this
therapeutic cancer vaccine. A randomized phase II chordoma study employing this vaccine is currently
in progress [149]. WRY induced antitumor immunity and improved survival rates in a murine model
of melanoma [150,151], and heat-inactivated whole yeast proved to be a better delivery system than
killed recombinant Leishmania in efforts to prevent high-risk HPV [152].
Cell-surface display has been widely used to optimize WRY by improving antigen targeting, giving
rise to YSD. In this approach, yeast cells are transformed with a single vector encoding a protein variant
of interest that is genetically fused to a cell-surface anchor protein. The anchor protein contains a signal
sequence that directs efficient transport of the fusion protein to the cell surface, where it is immobilized
and accessible to the extracellular space [153]. YSD has been mostly used in oral vaccines for animal
diseases including chicken coccidiosis [154], porcine pleuropneumonia [155] and porcine circovirus
associated disease [125], grass carp hemorrhagic disease [156] and fish infectious hematopoietic
necrosis [157]. Of note, in addition to stimulate humoral and cell-mediated immune responses, oral
administration of YSD has a positive impact on animal health through its direct nutritional effect [154].
Palma et al. [158] observed that probiotic YSD expressing HIV-1 gag protein induce CD8+ T-cell
response in HIV-1+ individuals, highlighting genetically engineered probiotic S. cerevisiae strains as
promising vectors for HIV vaccines. YSD has been also reported as a technology allowing rapid and
large-scale production of influenza vaccines [159]. Comprehensive lists of yeast-based vaccines for
human and animal diseases are described elsewhere [112,127,137].
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The latest advances in vaccinology have had a major effect on public and animal health.
However, efficient vaccines targeting important pathogens and cancer remain an ongoing challenge.
Vaccine-mediated protection might work best if the response is skewed towards a particular mechanism
such as cytotoxic, Th1-, or Th17-type responses and methods enabling this modulation are still poorly
developed. In this context, yeast adjuvant molecules and yeast-based vaccines hold great value in
human and veterinary medicine and might open new avenues for controlling and treating infectious
diseases and malignancies.
7. Concluding Remarks and Perspectives
Another use of yeast as a biotechnological tool is the production of recombinant EBV protein
for use as an EBV vaccine. Indeed, EBV is recognized as an important vaccine target, in particular
for cancer prevention and several efforts has been undertaken, most of them being focused on the
EBV glycoprotein gp350 which is the most abundant glycoprotein on the virus and on virus-infected
cells and the main target of naturally occurring neutralizing antibodies [23,160]. This way the yeast
Pichia pastoris, which is a popular workhorse for production of recombinant proteins, has been exploited
to express truncated forms of EBNA1 or gp350, both as secretory proteins with an N-terminal histidine
tag that allow their purification [161,162]. In both cases, the truncated EBV proteins retained good
immunogenicity and could therefore represent a useful source for developing EBV vaccine candidates.
Importantly these studies highlight that expression of various immunogenic EBV proteins in yeast
does not significantly alter their immunogenicity, which is consistent with the successful use of yeast
in general, and P. pastoris in particular, for the development of subunit vaccines against a wide range of
diseases caused by bacteria and viruses. In addition, S. cerevisiae has been used in the manufacture of a
dozen of approved vaccines against hepatitis B virus and one against human papillomavirus [163].
Hence, one can imagine to combine the expression of several EBV protein (e.g., EBNA1 and gp350)
as membrane associated proteins in the same yeast strain and to use these cells as WRY or YSD
vaccines, with the additional interest that they do not require special adjuvant as the yeast cell wall
itself represents an efficient adjuvant.
Another important point is that the aforementioned use of budding yeast to model the mechanism
at the basis of the immune evasion of EBV could be extended to other oncoviruses. For example,
similarly to EBV, the immune evasion of the oncogenic Kaposi sarcoma-associated virus (KSHV)
involves its genome maintenance protein LANA-1 which is also able to self-limit the translation of its
own mRNA [164] via a mechanism that, as for the EBNA1 protein of EBV, is probably based on G4
within the coding sequence of its own mRNA [44]. Hence, the same type of yeast-based approach than
the one developed for EBNA1 could be envisioned for other human oncovirus.
Hence, this review article dedicated to the link between yeast and immune response and evasion
nicely illustrates all the possible uses of yeast, from a popular model system to decipher basic cellular
regulatory pathways as well as pathophysiological mechanisms to a convenient and versatile tool for
chemical biology and for biotechnological and pharmacological applications [165], not to mention the
historical and essential use of yeast as a leavening agent and for alcoholic fermentation: now it is time
for a beer!
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